Oculis Holding Ag (OCSAW) — 6-K Filings

6-K Filings (23)

• 6-K Filing — Nov 10, 2025
• Oculis Holding AG Raises ~$110M in Share Offering — Oct 31, 2025 Risk: medium
  On October 29, 2025, Oculis Holding AG announced an offering of 5,432,098 ordinary shares at $20.25 per share. This offering was conducted through an underwriti
• Oculis Terminates $100M Share Sales Agreement — Oct 29, 2025 Risk: medium
  Oculis Holding AG announced on October 29, 2025, that it is terminating its at-the-market (ATM) sales agreement with Leerink Partners LLC, originally dated May
• Oculis Advances Privosegtor to Registrational Program After FDA Meeting — Oct 6, 2025 Risk: medium
  Oculis Holding AG announced on October 6, 2025, that its drug candidate, Privosegtor (OCS-05), will advance into a registrational program for neuro-ophthalmolog
• Oculis Holding AG Files 6-K with Financial Updates — Aug 21, 2025 Risk: low
  Oculis Holding AG filed a 6-K report as of June 30, 2025. The filing includes financial data and details related to warrants and stock options. Notably, it refe
• Oculis Holding AG Amends Loan Facility with Kreos Capital — Aug 1, 2025 Risk: low
  On July 31, 2025, Oculis Holding AG amended and restated its existing loan facility with Kreos Capital VII (UK) Limited, a fund managed by BlackRock, Inc. No fu
• Oculis Holding AG Reports AGM Results — Jun 5, 2025 Risk: low
  Oculis Holding AG held its 2025 Annual General Meeting on June 4, 2025, in Zug, Switzerland. Shareholders approved all proposed resolutions, including the adopt
• Oculis Holding AG Announces 2025 AGM Details — May 9, 2025 Risk: low
  Oculis Holding AG announced on May 9, 2025, the invitation to its 2025 Annual General Meeting (AGM) scheduled for June 4, 2025, in Zug, Switzerland. The filing
• Oculis Holding AG Reports Q1 2025 Financial Results — May 8, 2025 Risk: low
  Oculis Holding AG announced its unaudited financial results for the three-month period ended March 31, 2025, on May 8, 2025. The company is a foreign issuer fil
• Oculis Holding AG Updates Clinical Programs at R&D Day — Apr 15, 2025 Risk: medium
  On April 15, 2025, Oculis Holding AG held an R&D Day to provide updates on its clinical programs. Key highlights included progress on Phase 3 DIAMOND trials for
• Oculis Holding AG Raises $100M in Share Offering — Feb 14, 2025 Risk: medium
  On February 13, 2025, Oculis Holding AG entered into an underwriting agreement with BofA Securities Inc. and Leerink Partners LLC. This agreement is for an offe
• Oculis Holding AG Announces Positive Phase 2 Results for OCS-05 — Jan 6, 2025 Risk: medium
  On January 6, 2025, Oculis Holding AG announced positive topline results from its Phase 2 ACUITY trial for OCS-05. The trial met its primary safety endpoint and
• Oculis Holding AG Discloses Insider Transactions — Nov 29, 2024 Risk: low
  On November 29, 2024, Oculis Holding AG disclosed transactions by persons discharging managerial responsibilities (PDMRs) and their closely associated persons.
• Oculis Holding AG Reports Q3 2024 Unaudited Results — Nov 7, 2024 Risk: low
  Oculis Holding AG announced its unaudited results for the three and nine month periods ended September 30, 2024, on November 7, 2024. The filing includes interi
• Oculis Holding AG Files 6-K with Q2 2024 Financials — Aug 27, 2024 Risk: low
  Oculis Holding AG filed a 6-K report on August 27, 2024, detailing financial information as of June 30, 2024. The filing includes data on share-based compensati
• Oculis Holding AG Announces Positive Phase 2b Trial Results — Jun 10, 2024 Risk: medium
  Oculis Holding AG announced on June 10, 2024, positive topline results from its Phase 2b RELIEF trial for licaminlimab, a novel anti-TNFα biologic eye drop. The
• Oculis Holding AG Announces AGM Results and New Financing — May 31, 2024 Risk: medium
  Oculis Holding AG held its 2024 Annual General Meeting on May 29, 2024, announcing new appointments to its Board of Directors and Scientific Advisory Board. The
• Oculis Holding AG Q1 2024 Results Announced — May 8, 2024 Risk: low
  Oculis Holding AG announced its unaudited results for the first quarter ended March 31, 2024, on May 8, 2024. The filing incorporates by reference the company's
• Oculis Holding AG Announces 2024 AGM Details — Apr 29, 2024 Risk: low
  Oculis Holding AG announced its 2024 Annual General Meeting (AGM) will be held on May 29, 2024, in Zug, Switzerland. The company also furnished its 2023 Annual
• Oculis Raises $58.75M, Lists on Nasdaq Iceland — Apr 22, 2024 Risk: medium
  Oculis Holding AG announced on April 22, 2024, the successful closing of a registered direct offering, raising gross proceeds of $58.75 million. Additionally, t
• Oculis Holding AG Announces Registered Direct Offering — Apr 11, 2024 Risk: medium
  On April 11, 2024, Oculis Holding AG announced a registered direct offering to issue and sell 5,000,000 ordinary shares. The offering is being made to certain i
• Oculis Holding AG Reports 2023 Financial Results — Mar 19, 2024 Risk: low
  Oculis Holding AG announced its financial results for the fiscal year ended December 31, 2023, on March 18, 2024. The company filed a Form 6-K report with the S
• Oculis Holds R&D Day, Updates Clinical Programs & Leadership — Feb 28, 2024 Risk: medium
  Oculis Holding AG (Commission File No. 001-41636) held an R&D Day on February 28, 2024, issuing a press release to update on its clinical programs and announce

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX